Latest & greatest articles for finasteride

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on finasteride or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on finasteride and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for finasteride

21. Cost-effectiveness and cost-utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia

Cost-effectiveness and cost-utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia Cost-effectiveness and cost-utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia Cost-effectiveness and cost-utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia Canadian Coordinating Office for Health Technology Assessment Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Finasteride, 5 mg/day, for the treatment of benign prostatic hyperplasia (BPH) in elderly males. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Males, aged above 60 and experiencing symptoms

1995 NHS Economic Evaluation Database.

22. Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review

Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review Baladi JF, Menon D Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Baladi JF, Menon D. Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 1995 Authors' objectives To examine the cost-effectiveness of finasteride therapy in the treatment of benign prostatic hyperplasia

1995 Health Technology Assessment (HTA) Database.

23. Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia

Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral (...) ) treatment with finasteride, terazosin, and transurethral resection of the prostate for men (TURP). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical population of men aged 55-75 years with at least moderate symptoms of prostatism. Setting The practice setting was hospital. The economic study was carried out in the US. Dates to which data relate Effectiveness data were obtained between 1988-1994. Resource data were obtained between 1994-1995

1995 NHS Economic Evaluation Database.

24. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. (PubMed)

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissue-active form, dihydrotestosterone, by inhibiting the enzyme 5 alpha-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic (...) hyperplasia and therefore in symptoms of urinary obstruction.In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period.As compared with the men in the placebo group, the men treated with 5 mg

1992 NEJM